Janice Lu, MD, PhD

Articles by Janice Lu, MD, PhD

15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer

ByDiana Jaber,Natalie K Heater,Surbhi Warrior,Janice Lu, MD, PhD

July 3rd 2025

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

ByAditya Bardia, MD, MPH, FASCO,Javier Cortés, MD,Francois Clement Bidard,Guillermo Streich,José García-Sáenz,Janice Lu, MD, PhD ,Giulia Tonini,Simona Scartoni,Alessandro Paoli,Alessio Fiascarelli,Alessandro Bressan,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc

June 19th 2025

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

ByAditya Bardia, MD, MPH, FASCO,Joyce O’Shaughnessy, MD,Francois Clement Bidard,Phillipe Aftimos,Javier Cortes,Janice Lu, MD, PhD ,Giulia Tonini,Kathy Puyana Theall,Alessandro Paoli,Virginia Kaklamani, MD, DSc

August 24th 2024

Elacestrant Improves PFS in ESR1 mutated, ER+/HER2– Breast Cancer

ByJanice Lu, MD, PhD ,Rina Lokaj

December 28th 2023

Assessing for ESR1 Expression During Elacestrant for ER+ HER2– Breast Cancer

ByJanice Lu, MD, PhD ,Rina Lokaj

December 27th 2023

Future Uses of Elacestrant in Metastatic/Early-Stage Breast Cancer

ByJanice Lu, MD, PhD

December 22nd 2023

Latest Updated Articles

Future Uses of Elacestrant in Metastatic/Early-Stage Breast Cancer
December 22nd 2023

Trending on CancerNetwork

FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC

FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC

Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC

Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths

Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?